A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops

Eligible subjects were screened and randomly assigned to the placebo control group, the lower dose group, and the lower dose group. Subjects received the study drug in both eyes, 1 drop each time, once every night before sleep, for continuous administration.A total of 526 subjects were planned to be enrolled。

Statistical analyses were performed with the use of SAS software, version 9.4, without any specific description. All statistical tests were two-sided at a 0.05 level.

Inclusion criteria

• Child (female or male) aged 6 to 10 years.
• Myopia (SER of at least -0.50 D and no more myopic than -6.00 D) in each eye as measured by cycloplegic autorefraction.
• If present, astigmatism of ≤1.50 D in each eye as measured by cycloplegic autorefraction.
• Anisometropia SER of < 1.50 D as measured by cycloplegic autorefraction.

Exclusion criteria

• History of any disease or syndrome that predisposed the subject to severe myopia (e.g.,Marfan syndrome, Stickler syndrome, retinopathy of prematurity).
• History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus, lenticonus,spherophakia).
• Chronic use of any topical or systemic antimuscarinic/anticholinergic medications (e.g.,atropine, scopolamine, tropicamide) within 21 days prior to screening and/or anticipated need for chronic use during the study period (i.e., more than 7 consecutive days in 1 month or more than 30 total days in 1 year).

Use of cycloplegic drops for dilated ocular exam was allowable.

• Heart rate persistently (for more than 10 minutes) > 120 beats per minute.
• Allergy to study drugs.